Literature DB >> 35332660

Teledermatology: A useful tool also after COVID-19 era?

Matteo Megna1, Elisa Camela1, Alessia Villani1, Andrea Tajani1, Gabriella Fabbrocini1, Luca Potestio1.   

Abstract

Entities:  

Keywords:  COVID-19; patients management; teledermatology

Mesh:

Year:  2022        PMID: 35332660      PMCID: PMC9115067          DOI: 10.1111/jocd.14938

Source DB:  PubMed          Journal:  J Cosmet Dermatol        ISSN: 1473-2130            Impact factor:   2.189


× No keyword cloud information.

CONFLICT OF INTEREST

None.

AUTHOR CONTRIBUTIONS

Megna Matteo and Villani Alessia involved in conceptualization, validation, visualization, writing—original draft preparation, and writing—review and editing. Elisa Camela and Tajani Andrea involved in data curation, investigation, methodology, visualization, and writing—original draft preparation. Fabbrocini Gabriella involved in conceptualization, validation, visualization, writing—review and editing, and supervision. Luca Potestio involved in data curation, formal analysis, investigation, visualization, and writing—original draft preparation. All authors read and approved the final version of the manuscript.

ETHICAL APPROVAL

Authors declare human ethics approval was not needed for this study. Dear Editor, COVID‐19 pandemic period has definitively changed the routine medical practices. Among the strategies adopted to guarantee patients the best therapeutic outcomes, telemedicine has played a key role, particularly in dermatology. , Indeed, COVID‐19 restriction measures forced dermatologists to reduce their outpatient visits to urgent cases, referring to telemedicine for chronic conditions management. , , , In this period, dermatologists developed new solutions to guarantee their presence and therapeutic continuity for patients affected by chronic diseases. , In fact, different modalities of teledermatology services such as video calls, phone calls, WhatsApp and Facebook supporting groups, image evaluation, and e‐mails have been developed and implemented during COVID‐19 pandemic period in order to reduce the impact of COVID‐19 restriction measures on daily clinical practice. , In this letter, we want to hypothesize future applications and perspectives of teledermatology when the COVID‐19 pandemic period will end. Certainly, the reduction of COVID‐19 restrictions and the overcome of the social distancing will increase the number of face‐to‐face consultations, reducing the need for synchronous and asynchronous teleconsultations. However, teledermatology may remain a useful tool to guide and assist patients in their dermatologic conditions and therapies. The use of Facebook and WhatsApp supporting groups and e‐mails guided by physicians developed during COVID‐19 pandemic will allow to avoid the spreading of fake news and to continuously inform patients about their dermatologic condition. Moreover, teleconsultation may be a useful tool in patients with chronic pathologies to increase treatment compliance. In our opinion, teledermatology may be helpful, especially in chronic diseases such as psoriasis, atopic dermatitis, acne, and hidradenitis since the role of this weapon has been strongly investigated and reported during pandemic for these conditions. Psoriasis patients on maintenance therapy with biologics represent one of the major beneficiary of telemedicine due to the feasibility, convenience, and the capacity of saving time and money as demonstrated by Gisondi et al. Similar applications of telemedicine may be showed in other chronic dermatological diseases such as atopic dermatitis and hidradenitis suppurativa. In this contest, important limitations remain the incapacity to use video‐communication tools or message groups as well as technical issues due to insufficient computerization of ambulatories. Even if the consultations through teledermatology will reduce with the decrease of COVID‐19 restrictions, this tool will remain a useful strategy to monitor and assist patients in their disease and their treatment. Moreover, this strategy will remain the main weapon in patients who cannot attend to face‐to‐face consultation due to quarantine measures and other personal problems who need disease assessment and therapies monitoring as well as several chronic dermatological diseases such as psoriasis may benefit from telemedicine in daily clinical practice. In conclusion, COVID‐19 pandemic period has strongly changed the conception of medicine. Among the new strategies developed and implemented to fight against social distancing measures, telemedicine has played a key role. Clinicians should keep in mind the utility of this weapon and the possibility of a future role of teledermatology in daily clinical practice. Surely, teledermatology will remain in dermatologic clinical practice since, thanks to COVID‐19 restriction measures, dermatologic clinical practice is changed.
  9 in total

1.  Teledermatology: a useful tool to fight COVID-19.

Authors:  Alessia Villani; Massimiliano Scalvenzi; Gabriella Fabbrocini
Journal:  J Dermatolog Treat       Date:  2020-04-13       Impact factor: 3.359

2.  Teledermatology and chronic skin diseases: Real life experience in a Southern Italian Dermatologic Centre.

Authors:  Alessia Villani; Matteo Megna; Massimiliano Scalvenzi; Gabriella Fabbrocini; Angelo Ruggiero
Journal:  Dermatol Ther       Date:  2020-06-15       Impact factor: 2.851

3.  Dermatological consultations in the COVID-19 era: is teledermatology the key to social distancing? An Egyptian experience.

Authors:  Pakinam I N Mostafa; Amira Aly Hegazy
Journal:  J Dermatolog Treat       Date:  2020-07-07       Impact factor: 3.359

4.  Strategies to maximize clinical efficiency while maintaining patient safety during the COVID-19 pandemic: an interview-based study from private practice dermatologists.

Authors:  Kaitlyn M Yim; Rebecca M Yim; Sara Gaspard; Jamie MacDougall; April W Armstrong
Journal:  J Dermatolog Treat       Date:  2020-10-21       Impact factor: 3.359

5.  Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs.

Authors:  Paolo Gisondi; Francesco Bellinato; Stefano Piaserico; Sara Di Leo; Simone Cazzaniga; Luigi Naldi
Journal:  Dermatol Ther (Heidelb)       Date:  2021-06-25

6.  Teledermatology: A useful tool also after COVID-19 era?

Authors:  Matteo Megna; Elisa Camela; Alessia Villani; Andrea Tajani; Gabriella Fabbrocini; Luca Potestio
Journal:  J Cosmet Dermatol       Date:  2022-04-11       Impact factor: 2.189

7.  Teledermatology for patient management, dermatology education and research during the COVID-19 pandemic.

Authors:  Eleonora Cinelli; Matteo Megna; Adriana Di Guida; Vincenzo Greco; Maria Carmela Annunziata; Gabriella Fabbrocini
Journal:  Australas J Dermatol       Date:  2020-05-14       Impact factor: 2.875

8.  Dermatology practices as vectors for COVID-19 transmission: A call for immediate cessation of nonemergent dermatology visits.

Authors:  Shawn G Kwatra; Ronald J Sweren; Anna L Grossberg
Journal:  J Am Acad Dermatol       Date:  2020-03-22       Impact factor: 15.487

  9 in total
  6 in total

1.  Comment on Marasca et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. J. Clin. Med. 2022, 11, 1511.

Authors:  Francesco Borgia; Federica Li Pomi; Clara Alessandrello; Sebastiano Gangemi
Journal:  J Clin Med       Date:  2022-07-14       Impact factor: 4.964

2.  Reply to Borgia et al. Comment on "Marasca et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. J. Clin. Med. 2022, 11, 1511".

Authors:  Luca Potestio; Luigi Fornaro; Fabrizio Martora; Vincenzo Picone; Gabriella Fabbrocini; Claudio Marasca
Journal:  J Clin Med       Date:  2022-07-21       Impact factor: 4.964

3.  Comment on 'Morphoea following COVID-19 vaccination'.

Authors:  Fabrizio Martora; Teresa Battista; Angelo Ruggiero; Gabriella Fabbrocini; Luca Potestio
Journal:  Clin Exp Dermatol       Date:  2022-09-02       Impact factor: 4.481

4.  Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: What we should know?

Authors:  Luca Potestio; Alessia Villani; Gabriella Fabbrocini; Fabrizio Martora
Journal:  J Cosmet Dermatol       Date:  2022-08-26       Impact factor: 2.189

5.  Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics.

Authors:  Matteo Megna; Luca Potestio; Teresa Battista; Elisa Camela; Lucia Genco; Matteo Noto; Gabriella Fabbrocini; Fabrizio Martora
Journal:  Clin Exp Dermatol       Date:  2022-09-02       Impact factor: 4.481

6.  Teledermatology: A useful tool also after COVID-19 era?

Authors:  Matteo Megna; Elisa Camela; Alessia Villani; Andrea Tajani; Gabriella Fabbrocini; Luca Potestio
Journal:  J Cosmet Dermatol       Date:  2022-04-11       Impact factor: 2.189

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.